As inflammasome activation and IL-1β play a critical role in the development of hepatic inflammation and steatosis, blocking the inflammasome pathway or IL-1/IL-1R pathways could represent a novel approach for the treatment of liver inflammation and injury. Here, IL1B is linked to inflammation.